URGN · All filings · Read this filing
What changed 10-Q
Item 1. Legal Proceedings
2025-05-12 compared with 2024-11-06 · 2 added, 0 removed, 12 unchanged (14% of the section changed)
8 unchanged sentences
The lawsuit follows an Abbreviated New Drug Application filed by Teva Pharmaceuticals, Inc., which seeks authorization from the FDA to manufacture, use or sell a generic version of mitomycin for pyelocalyceal solution, 40 mg/vial in the United States before the expiry of the two patents referenced above.
+Added: By order dated February 27, 2025, the court approved the parties’ joint stipulation to remove the Markman hearing and any related claim-construction proceedings from the court’s calendar.
+Added: This matter is scheduled for a bench trial in October 2026.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.